^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SPARC underexpression

    i
    Other names: SPARC, Secreted Protein Acidic And Cysteine Rich, BM-40, Secreted Protein Acidic And Rich In Cysteine, Basement-Membrane Protein 40, Osteonectin, SPARC, ONT, ON, Secreted Protein, Acidic, Cysteine-Rich (Osteonectin), Cysteine-Rich Protein, OI17
    Entrez ID:
    6678
    Related biomarkers:
    Expression
    CNA
    Others
    over1year
    Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression. (PubMed, Mol Ther Nucleic Acids)
    NSCLC patients with high SPARC expression could benefit more compared to low-SPARC-expression patients with cisplatin treatment. Overall, our comprehensive analysis of cell-specific APA events shed light on the regulatory mechanism of cell-specific oncogenes and provided opportunities for combination of APA-regulated therapeutic target and cell-specific therapy development.
    Journal
    |
    SPARC (Secreted Protein Acidic And Cysteine Rich)
    |
    SPARC overexpression • SPARC underexpression
    |
    cisplatin
    over1year
    Impact of SPARC expression on pembrolizumab treatment response and prognostic role in advanced stage non-small cell lung cancer. (ASCO 2023)
    Our study lightened a new area in the literature that SPARC expression might predict the pembrolizumab response and might be a marker for CNS progression in NSLC patients. These results should be explored in further studies to address the potential therapeutic implications of SPARC expression.
    PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • SPARC (Secreted Protein Acidic And Cysteine Rich)
    |
    PD-L1 expression • SPARC underexpression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab)